Our Approach
Ardan Pharma is developing a first-in-class targeted immunotherapy based on small-molecule modulators of the transmembrane cation channel TMEM176A/B.
TMEM176A/B has recently emerged as a novel oncology target and potential predictive biomarker and recognized as a key mediator of resistance to current oncological standards of care.
Targeting TMEM176A/B directly rewires innate and adaptive anti-tumoral immune response as well as key processes in malignant cell biology.
We have built a portfolio of drug candidates that induce pharmacologic modulation of TMEM176A/B and currently advancing on the transition from pre-IND to a clinical-stage asset.
